Drug Profile
SB 728 HSPC
Alternative Names: SB-728-HSC; SB-728-HSPC; SB-728mR-HSPCLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Sangamo BioSciences
- Developer City of Hope National Medical Center; Sangamo Therapeutics; University of Southern California
- Class Cell therapies; Stem cell therapies; Zinc finger DNA binding proteins
- Mechanism of Action CCR5 receptor modulators; Cell replacements; Gene silencing
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for phase-I development in HIV-infections in USA (Parenteral, Infusion)
- 11 Jul 2019 SB-728-HSPC is still in phase I development in HIV-infections in USA (Parenteral, Infusion) (Sangamo-Therapeutics pipeline July 2019) (NCT02500849)
- 06 Jan 2017 Sangamo Biosciences is now called Sangamo Therapeutics